Since the B cell receptor (BCR) pathway is constitutively activated in both ABC and GCB DLBCL, Sasi BK et al. (2019) [178] showed SYK or BTK inhibition synergistically enhances the responsiveness of venetoclax in both BCL-2-positive DLBCL cell lines in vitro and in vivo in the xenograft mouse model. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.